"PhoreMost is at an incredibly exciting phase of development, where we are now progressing our high-value oncology and inflammation degrader programs towards preclinical studies," said Dr. Torbett.
"This funding milestone is pivotal for the company's growth, allowing us to solidify our leadership in the next-generation degrader field and accelerate our pipeline advancements," Dr. Torbett remarked.
"At the heart of PhoreMost's innovation is its SITESEEKER platform, designed to identify and target disease-causing proteins previously deemed undruggable, crucial for our drug discovery process."
"One of PhoreMost's key innovations is its recently launched GlueSEEKER platform, enabling the degradation of disease-causing proteins by discovering molecular glues that facilitate protein-protein interactions."
Collection
[
|
...
]